6 unknown, 5 completed, 2 active not recruiting, 1 enrolling by invitation. 5 Phase 1, 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 4, Completed 1 |
| Phase 2 | 5 | Unknown 3, Completed 2 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Shanghai Zerun Biotechnology Co.,Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris) - Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia | Enrolling by invitation | Shanghai Zerun Biotechnology Co.,Ltd | 486 | 2024-08-30 | 2026-09-22 | |
| Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women HPV-16/18 vaccine, Placebo - Cervical Cancer, Vulvar Cancer | Active not recruiting | Shanghai Zerun Biotechnology Co.,Ltd | 5372 | 2023-03-27 | 2025-01-15 | |
| Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004 Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris) - Human Papillomavirus Infection | Active not recruiting | Shanghai Zerun Biotechnology Co.,Ltd | 348 | 2023-03-25 | 2026-09-17 | |
| Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Zerun HPV-9, GARDASIL ®9 - Cervical Cancer, Genital Wart | Phase 3 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 1200 | 2022-09-01 | 2022-10-28 |
| Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults. ZR202-CoV, ZR202a-CoV, Comirnaty® - SARS-CoV-2 Infection, COVID-19 | Phase 1 / Phase 2 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 60 | 2022-06-02 | 2023-04-20 |
| Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 ZR-202-CoV, Placebo - COVID-19 | Phase 1 / Phase 2 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 84 | 2022-01-18 | 2023-04-19 |
| Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose - COVID-19 | Phase 2 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 528 | 2021-07-31 | 2023-04-19 |
| Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose - COVID-19 | Phase 1 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 72 | 2021-07-12 | 2023-04-19 |
| Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris) - HPV Infection | Phase 3 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 1100 | 2021-04-20 | 2023-04-13 |
| A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine HPV Vaccine, Placebo - HPV Infections | Phase 1 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 90 | 2019-03-09 | 2023-04-13 |
| Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females HPV-16/18 vaccine - Human Papillomavirus, Cervical Intraepithelial Neoplasia | Phase 2 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 900 | 2016-02-01 | 2023-04-13 |
| A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. HPV-16/18 vaccine, HPV-16/18 placebo - Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 3 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 12000 | 2014-11-02 | 2022-12-19 |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females HPV vaccine, Placebo - Human Papillomavirus | Phase 2 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 1200 | 2013-09-01 | 2023-04-13 |
| Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females HPV 16/18 vaccine, 0,5ml, Placebo control, 0.5ml, HPV 16/18 vaccine, 1.0ml - Human Papillomavirus | Phase 1 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 160 | 2012-02-01 | 2012-03-08 |
Papillomavirus Infections (6) · Uterine Cervical Neoplasms (5) · COVID-19 (4) · Uterine Cervical Dysplasia (4) · Condylomata Acuminata (2) · Persistent Infection (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Papillomavirus Vaccines (2) · Vaccines (2) · BNT162 Vaccine (1) · ZR-202-CoV COVID-19 vaccine (1) · ZR202-CoV COVID-19 vaccine (1)
China (12) · Mali (1)
Zhaojun Mo (2) · Rong-cheng Li, MD (1) · Samba Sow (1) · Ting Huang (1) · Yan-ping Li, MD (1)